Utang jangka cendhak perusahaan: BioNexus Gene Lab Corporation (BGLC)

BioNexus Gene Lab Corp. (BGLC) combines industrial chemical supplies with the development of genetic tests in Asia, balancing sector volatility. Short-term borrowings of up to one year demonstrate liability dynamics, where 0.00 reflects the latest metric value. Cancer diagnostics provide inflation resistance due to inelastic demand. Meanwhile, current liquidity and stable working capital fully cover the business's operational requirements.

This metric aggregates all BioNexus Gene Lab Corp. (BGLC) obligations with maturities of up to one year, measuring short-term liquidity and the risk of credit pressure. Stable revenue from the sale of diagnostic tests in Southeast Asia allows the company to manage capital effectively, which is reflected in the price action of current debt on loans and borrowings as an indicator of financial stability.